PeproMene Bio Reports Breakthrough Phase 1 Clinical Trial Results for BAFF-R-Targeted CAR T-cell Therapy in B-cell Lymphomas

PeproMene Bio, Inc. has announced the publication of Phase 1 clinical trial results in The Lancet, demonstrating deep and durable complete responses for its first-in-class BAFF-R-targeted CAR T-cell therapy, PMB-CT01, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The study reported an 80% complete response rate, including in patients who had previously failed CD19-directed CAR T-cell therapy, with all complete responses ongoing at the data cutoff. The therapy also showed a favorable safety profile, with all cytokine release syndrome events and reported neurotoxicity events being Grade 1.